By Rishika Sadam Feb 16 (Reuters) - Biocon is aiming for high-double-digit percentage revenue growth as the Indian ...

Biocon Q3 FY26 Results: Revenue Up 11% YoY to ₹4,290 Cr 📈 | MCap 59,195.55 Cr • Total revenue reached ₹4,290 Cr, up 11% year ...

After cutting debt and raising $1 billion, Biocon sharpens its biosimilars and GLP-1 play, betting on scale, regulatory ...

Biocon, an Indian pharmaceutical firm, is planning a global launch of generic weight-loss drugs, aiming for high double-digit percentage revenue growth.

ABU DHABI (Reuters) - India's biggest biotech firm Biocon Ltd expects revenue to double to $1 billion in four years as it expands in Europe and the United States with new products, its chairperson and ...

New insulin treatments for diabetes are hitting the market fast and furious these days. Biocon Biologics’ effort to move its insulin through the approval process in India, however, has landed the ...

Shares of Indian drugmaker Biocon Ltd fell about 12% on Monday after the company said its unit Biocon Biologics would buy U.S.-based Viatris Inc's biosimilars business in a transaction valued at $3.34 ...

BENGALURU, Dec 9 (Reuters) - Indian drugmaker Biocon Ltd BION.NS is in talks with generic drugmaker Mylan for a merger of their biosimilar businesses,financial newswebsite Moneycontrol reported on ...

Biocon already has a wide pipeline of biosim molecules and partnerships with global drugmakers. Now, it’s picked up a 60,000-square-foot R&D site from Pfizer to advance on its ambitions in biosimilars ...

India’s Biocon Ltd has received regulatory approval for its drug Itolizumab to be used on coronavirus infected patients suffering from moderate to severe respiratory distress, the biopharmaceutical ...